Prevail Therapeutics appoints general counsel
New York-based gene therapy company Prevail Therapeutics has recruited Kira Schwartz to fill the new role of general counsel.
Schwartz was previously senior vice president, associate general counsel and assistant secretary at Allergan – formerly Actavis, which adopted the Allergan name after buying it in 2015 – where she was in charge of a legal group supporting corporate governance, business development, finance, human resources, supply chain and real estate functions. Schwartz led Actavis’ $70.5 billion acquisition of Allergan as vice president and associate general counsel at Actavis.
Before that, she held senior leadership positions at Forest Laboratories, which was acquired by Actavis. In that capacity she oversaw areas including business development, manufacturing and supply chain and R&D. Earlier in her career she was senior corporate counsel in Pfizer’s business transactions group and worked at law firm Cleary Gottlieb Steen & Hamilton.
Nasdaq-listed Prevail is a biotechnology company developing what it calls potentially disease-modifying gene therapies for patients with neurodegenerative diseases.
‘We are excited to welcome Kira to Prevail as our general counsel and latest member of our executive team,’ says Asa Abeliovich, founder and CEO, in a statement. ‘Prevail will greatly benefit from Kira’s significant expertise as a senior legal counselor within the biopharmaceutical industry. She will play a key role in shaping our internal legal function and advising the board and leadership team on all legal and corporate governance issues as we continue to advance our AAV gene therapy-based pipeline through the clinic for patients with neurodegenerative diseases.’